The influence of immunosuppressants on direct‐acting antiviral therapy is dependent on the hepatitis C virus genotype
- 7 November 2017
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 20 (1) , e12803
Abstract
Background: Direct‐acting antivirals (DAAs) have substantially increased sustained virological response rates after liver transplantation, with improved tolerance compared to interferon‐based therapy. The influence of immunosuppressive agents on the efficacy of DAAs has not been clarified.Methods: Subgenomic hepatitis C virus (HCV) replicons for genotype (GT) 1b, 2b, 3a, and 4a were treated with the mammalian target of rapamycin (mTOR) inhibitors everolimus and sirolimus or with the calcineurin inhibitors (CNIs) cyclosporine or tacrolimus, either alone or in combination with selected DAAs. Cell proliferation‐related effects were excluded with MTT assays. HCV replication activity was quantified by quantitative real‐time polymerase chain reaction or luciferase assay.Results: Addition of either mTOR inhibitor to the DAA daclatasvir (DAC) resulted in a 30% increase in antiviral activity compared to DAC alone for HCV GT2a, GT3a, and GT4a (all P ≤ .01). Similar results were obtained using sofosbuvir and ledipasvir. In contrast, addition of either mTOR inhibitor to DAC induced a 30% reduction in antiviral activity in GT1b cells (P ≤ .01 vs DAC alone). Neither CNI affects the antiviral activity of the DAAs in any HCV GT.Conclusion: For patients with HCV GT2a, GT3a, or GT4a infection, mTOR‐based immunosuppressive therapy may be beneficial. CNI‐based therapy may be more efficacious in GT1b patients, as mTOR inhibitors seem to impair antiviral efficacy of DAAs in HCV GT1b infection.Keywords
Funding Information
- Novartis
This publication has 24 references indexed in Scilit:
- Host mTORC1 Signaling Regulates Andes Virus ReplicationJournal of Virology, 2013
- Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma CellsAntimicrobial Agents and Chemotherapy, 2012
- Hepatitis C Virus NS5A Activates the Mammalian Target of Rapamycin (mTOR) Pathway, Contributing to Cell Survival by Disrupting the Interaction between FK506-binding Protein 38 (FKBP38) and mTORJournal of Biological Chemistry, 2010
- IFN-α–Induced Apoptosis in Hepatocellular Carcinoma Involves Promyelocytic Leukemia Protein and TRAIL Independently of p53Cancer Research, 2009
- Overview of immunosuppression in liver transplantationWorld Journal of Gastroenterology, 2009
- Diverse Effects of Cyclosporine on Hepatitis C Virus Strain ReplicationJournal of Virology, 2006
- Management of HCV Infection and Liver TransplantationInternational Journal of Medical Sciences, 2006
- Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantationLiver Transplantation, 2005
- Suppression of Hepatitis C Virus Replication by Cyclosporin A Is Mediated by Blockade of CyclophilinsGastroenterology, 2005
- Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell LineScience, 1999